
Gaithersburg-based Emergent BioSolutions has made the decision to cut 400 jobs and scale back operations at some its facilities, instead focusing on core products such as overdose reversal nasal spray Narcan and anthrax vaccines. The company is also eliminating its chief operating officer (COO) position. According to WTOP, “the job cuts are at Emergent’s Bayview facility in Baltimore, at its drug production facility in Rockville, as well as another facility in Canton, Massachusetts.”
In March, the FDA granted the over-the-counter approval of Narcan to Emergent BioSolutions. It became the first naloxone product approved for use without a prescription. “Emergent’s business pivot is expected to result in yearly savings of more than $100 million, the company explained. The moves will cost Emergent around $20 million—costs it expects to incur in the third quarter of 2023.” according to FiercePharma.
Featured photo courtesy of Google Maps.
Recent Stories
So What Else Indoor Vintage Event
SATURDAY 12/9/23 Join us for the ultimate year-end celebration of art, vintage finds, and fashion at CNXN.WORLD's Art & Vintage Event! Sponsored by So What Else, Inc. We will be hosting a hygiene product drive as well! Please bring items like soap, toothpaste, shampoo, deodorant, and more to donate and make a difference. Sign up for a chance to WIN a $40 credit you can use towards any purchase at the event! We've got food, drinks, and more prizes during the event! Vendor Lineup: @thefoundrymd @poetic_sole @on2thenext_vntg @fleetwoodmarket @anatething @bimdayz @thriftlifeadvintage @yester_dayz @bratty_couture @camryncurtiss @crushthrifts @888deadgirl @ken_blendz @misfitbodega @mando.nc @mozartsthriftshop @seamslikenew @skuffstore @the.crucial.cookie @sowhatelsehelps Saturday, December 9th, 20231:30 PM to 6:00 PM4924 Wyaconda Rd, North Bethesda, MD 20852. See you there!